Bystolic Advisory Committee: Trial Shortcomings Could Mean Tough Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Single pivotal trail for Forest's beta blocker may produce a skeptical audience on Jan. 11, when an FDA advisory committee evaluates the additional requested indication for chronic heart failure.
You may also be interested in...
Forest Should Conduct More Bystolic Studies For CHF Approval, Panel Says
An FDA panel decided that the agency should not approve Forest Laboratories' Bystolic (nebivolol) for chronic heart failure based on the current evidence, but suggested the drug could be approved for this added indication if the drug maker conducts a non-inferiority trial against other beta-blockers
Forest Should Conduct More Bystolic Studies For CHF Approval, Panel Says
An FDA panel decided that the agency should not approve Forest Laboratories' Bystolic (nebivolol) for chronic heart failure based on the current evidence, but suggested the drug could be approved for this added indication if the drug maker conducts a non-inferiority trial against other beta-blockers
For Forest, No Single Silver Bullet But Many Opportunities
There is no quick fix to guide Forest Laboratories through 2012, when its best-seller, the antidepressant Lexapro, goes off patent. But management thinks it will have enough patches in place by then to compensate for lost revenues and avert disaster